The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Boston Scientific's revenues will drop -5.6% and EPS will increase 10.0%.
The average estimate for revenue is $1.77 billion. On the bottom line, the average EPS estimate is $0.11.
Last quarter, Boston Scientific reported revenue of $1.83 billion. GAAP reported sales were 7.4% lower than the prior-year quarter's $1.98 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.11. GAAP EPS were -$2.51 for Q2 compared to $0.10 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 65.9%, 280 basis points better than the prior-year quarter. Operating margin was 13.5%, 100 basis points worse than the prior-year quarter. Net margin was -195.7%, 20,310 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $7.28 billion. The average EPS estimate is $0.42.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 751 members out of 936 rating the stock outperform, and 185 members rating it underperform. Among 187 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 166 give Boston Scientific a green thumbs-up, and 21 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Boston Scientific is hold, with an average price target of $6.84.
- Add Boston Scientific to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Big-Cap Stocks That Are Growing Again
Pfizer, Inc. Microsoft Corp, and Boston Scientific are back on their feet and growing again and that may make now a good time to buy them in portfolios.
These 3 Heart Disease Stocks Are Trouncing the S&P 500 This Year
Returns are sky-high this year for med-tech companies Edwards Lifesciences, Abiomed, and Boston Scientific.
Why Boston Scientific Corporation Rose 15.7% in April
A stellar earnings report pumped up shares of the cardiac device specialist.